Meditech Cold Sore (HSV-1) Clinical Trials set to commence at Boston University

Patients can now register to participate in Herpes Simplex 1 (Cold Sore) Study

   COMPANY NEWS - MEDITECH PHARMACEUTICALS, INC.

Meditech Cold Sore (HSV-1) Clinical Trials set to commence at Boston University.

SCOTTSDALE, AZ, January 14, 2002
Meditech Pharmaceuticals, Inc. (MDCH-OTC: BB) Meditech announced today that it has received final IRB (Independent Review Board) approval for commencement of its cold sore (HSV-1) clinical trials at Boston University. The website address for the clinical trials is http://icrc.bumc.bu.edu/. People who wish to qualify and enroll for the study will be able to do so at that website beginning the week of January 28, 2002.
Meditech shareholders are being asked not to apply for admission to the study so as to preserve the complete and total impartiality of the study. The Company will make arrangements to accommodate its shareholders separately from the study.
Meditech Chairman and CEO Gerald Kern states, We are very pleased that the study is about to begin. To insure that the results of this study be totally independent, we have decided not to enroll Meditech shareholders, employees or affiliates as patients. We will arrange to accommodate them outside of the clinical trials. Details of the shareholder/affiliate program will be posted on the Companys website -- www.mdch.net. "
Separately, Meditech has been notified by the United States PTO (Patent and Trademark Office) that the Zilex trademark has been allowed for use.
Meditech is a drug development company focused on the development of human, veterinary and agricultural antimicrobial agents. Meditech was founded in 1982 as Medical Technology Corporation of America and went public via an IPO in 1983.
Media Contact:

Steven Kern
Meditech Pharmaceuticals, Inc.
Tel: (480) 614-2874
Fax: (480) 614-0560
Internet: http://www.mdch.net
E-mail: coo@mdch.net